Resilience and Lifera plan for new biopharma manufacturing capacity in Riyadh, Saudi Arabia.
The proposed biopharma manufacturing facility represents a significant step towards building resilience and enhancing the lifera plan for the development of the biopharmaceutical industry.
The key features of this facility is its capacity to support the aseptic filling of a wide range of pharmaceutical products, including inactivated and bacterial vaccines, mRNA vaccines, monoclonal antibodies, plasma-derived products, and large molecules.
With a target production capacity of more than 125 million units annually, this facility will significantly contribute to meeting the growing demand for these essential medical products.
Initially focusing on manufacturing priority molecules, the facility also has strategic plans to export its products to the Gulf Cooperation Council (GCC) countries.
By advancing biopharmaceutical supply chains and enhancing manufacturing capabilities, this project aims to ensure a more reliable and robust response to public health crises and healthcare needs worldwide.
Name National Resilience & Lifera
Type New Construction